Influence of apolipoprotein E ɛ4 on rates of cognitive and functional decline in mild cognitive impairment
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Background: Apolipoprotein E ɛ4 (APOE ɛ4) allele carrier status has been well established as a risk factor for developing Alzheimer's disease. However, the specific influence of APOE ɛ4 allele status on cognitive and functional rates of decline in mild cognitive impairment (MCI) is poorly understood. We examine the prospective association of APOE ɛ4 allele status on measures of cognitive and functional decline in subjects with amnestic MCI (aMCI). Methods: A total of 516 aMCI participants aged 55–90 years who received placebo or vitamin E from the Alzheimer's Disease Cooperative Study's MCI treatment trial were evaluated. During the 36‐month study period, neurocognitive and functional measures were collected. These measures were assessed over time for change and association with APOE ɛ4 status. Generalized Estimating Equations were performed to model each outcome measure over the study period. Results: APOE ɛ4 status had a significant impact on cognitive and functional decline on multiple measures; those who were APOE ɛ4 positive had significantly more rapid decline in performance on all cognitive and functional measures except Number Cancellation and Maze tracing (P < .05). The greatest decline was seen in global measures of cognition and function including the Clinical Diagnostic Rating scale, followed by the Mini‐Mental State Examination, Global Deterioration scale, and the Alzheimer's Disease Assessment Scale‐Cognitive Subscale. Conclusions: These findings demonstrate that APOE ɛ4 genotype is predictive of increased general rates of decline with global measures of cognition and function most affected. With accelerated declines in common clinical trial primary efficacy measures, APOE ɛ4 status needs to be accounted for in treatment trials of MCI.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Petersen, R. C., Stevens, J. C., Ganguli, M., Tangalos, E. G., Cummings, J. L., & DeKosky, S. T. (2001) · Neurology · doi:10.1212/wnl.56.9.1133 · Cited by 2,065
Self-citationVitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
Petersen, R. C., Thomas, R. G., Grundman, M., Bennett, D., Doody, R., Ferris, S., Galasko, D., Jin, S., Kaye, J., Levey, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050151 · Cited by 1,844 · cited 7×
“In the primary analysis of the ADCS donepezil and vitamin E treatment trial, there was no treatment effect in the full cohort at 36 months, yet the APOE 34 subset saw a significant treatment effect out to 36 months, with a one-third reduction in conversions to AD in those subjects on donepezil [8].”
BackgroundMethodInfluentialSelf-citationGrundman, M. (2004) · Archives of Neurology · doi:10.1001/archneur.61.1.59 · Cited by 972 · cited 1×
“Cognitive and functional scores were obtained from participants in the ADCS randomized clinical drug trial of donepezil, vitamin E, or placebo investigating progression from aMCI to AD over 36 months, conducted between March 1999 and January 2004 [8,21].”
MethodReiman, E. M., Chen, K., Liu, X., Bandy, D., Yu, M., Lee, W., Ayutyanont, N., Keppler, J., Reeder, S. A., Langbaum, J. B. S., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900345106 · Cited by 785 · cited 1×
“This association with worsened early cognitive status and decline is accompanied by evidence of increased AD pathology associated with APOE 34 in cognitively normal individuals [43], MCI [44], and AD [45].”
BackgroundNeuropsychological tests accurately predict incident Alzheimer disease after 5 and 10 years
Tierney, M. C., Yao, C., Kiss, A., & McDowell, I. (2005) · Neurology · doi:10.1212/01.wnl.0000163773.21794.0b · Cited by 274 · cited 1×
“This makes intuitive sense considering that episodic memory impairment is well described as one of the earliest abnormalities in MCI and AD [16,47].”
BackgroundEffect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease
Drzezga, A., Grimmer, T., Henriksen, G., Mühlau, M., Perneczky, R., Miederer, I., Praus, C., Sorg, C., Wohlschläger, A., Riemenschneider, M., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a2e8d0 · Cited by 248 · cited 1×
“This association with worsened early cognitive status and decline is accompanied by evidence of increased AD pathology associated with APOE 34 in cognitively normal individuals [43], MCI [44], and AD [45].”
BackgroundNeuropsychological Prediction of Decline to Dementia in Nondemented Elderly
Kluger, A., Ferris, S. H., Golomb, J., Mittelman, M. S., & Reisberg, B. (1999) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/089198879901200402 · Cited by 227
Ewers, M., Zhong, Z., Bürger, K., Wallin, A., Blennow, K., Teipel, S. J., Shen, Y., & Hampel, H. (2008) · Brain · doi:10.1093/brain/awn034 · Cited by 119
Cited by
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459
The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease
Hampel, H., Mesulam, M.-M., Cuello, A. C., Farlow, M. R., Giacobini, E., Grossberg, G. T., Khachaturian, A. S., Vergallo, A., Cavedo, E., Snyder, P. J., et al. (2018) · Brain · doi:10.1093/brain/awy132 · Cited by 1,918
Kueper, J. K., Speechley, M., & Montero-Odasso, M. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170991 · Cited by 424
Vitamin E for Alzheimer's dementia and mild cognitive impairment
Farina, N., Llewellyn, D., Isaac, M. G. E. K. N., & Tabet, N. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002854.pub5 · Cited by 413
Anti-inflammatories in Alzheimer’s disease—potential therapy or spurious correlate?
Rivers-Auty, J., Mather, A. E., Peters, R., Lawrence, C. B., & Brough, D. (2020) · Brain Communications · doi:10.1093/braincomms/fcaa109 · Cited by 130
Metadata
- Authors
- Whitehair, D. C., Sherzai, A., Emond, J., Raman, R., Aisen, P. S., Petersen, R. C., Fleisher, A. S., & Study, A. D. C.
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2010-09
- Volume
- 6
- Issue
- 5
- Pages
- 412-419
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W1967607566
- Cited by
- 70
- References
- 8
- FWCI
- 3.19
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Influence of apolipoprotein E ɛ4 on rates of cognitive and functional decline in mild cognitive impairment. https://app.cochat.ai/papers/10.1016/j.jalz.2009.12.003
- The paper
- Whitehair, D. C., Sherzai, A., Emond, J., Raman, R., Aisen, P. S., Petersen, R. C., Fleisher, A. S., & Study, A. D. C. (2010). Influence of apolipoprotein E ɛ4 on rates of cognitive and functional decline in mild cognitive impairment. Alzheimer's & Dementia. https://doi.org/10.1016/j.jalz.2009.12.003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.